{"product_id":"henlius-business-model-canvas","title":"Shanghai Henlius Biotech Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHenlius Business Model Canvas: Biosimilar-to-Biologic Playbook for Investors \u0026amp; Strategists\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Shanghai Henlius Biotech’s business model—this concise Business Model Canvas exposes how the company creates clinical and commercial value, leverages partnerships, and monetizes biosimilars and biologics to scale in China and abroad; ideal for investors, strategists, and founders seeking actionable insights and ready-to-use Word\/Excel templates to benchmark or adapt proven pharma strategies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Synergy with Fosun Pharma\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs a core subsidiary of Fosun Pharma (Shanghai Fosun Pharmaceutical Group Co., Ltd.), Henlius gains integrated financial backing—Fosun Pharma reported RMB 76.6 billion revenue in 2024—plus access to its nationwide sales network covering 2,500+ hospitals, boosting Henlius’ market reach and reimbursement penetration. This tie gives Henlius steady capital for capital-intensive R\u0026amp;D (R\u0026amp;D spend in Fosun Pharma 2024: RMB 4.8 billion) and credibility in China’s healthcare sector, supporting long-term growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Distribution Alliances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHenlius partners with international pharma leaders—Organon, Sandoz, and Accord Healthcare—granting direct commercial channels into the US, EU, and 50+ emerging markets; these alliances helped drive Henlius’ 2024 international biosimilar revenue to about US$120m (company filings, 2024).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Research Collaborations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHenlius partners with top universities and institutes—including Fudan University and Shanghai Institute of Materia Medica—to co-develop early-stage oncology and immunology leads, sharing lab resources and IP where 2024 R\u0026amp;D spend hit RMB 1.02 billion (up 18% YoY). These ties give Henlius faster access to novel biologics and CRISPR\/ADC platforms, keeping its pipeline aligned with academic trends and reducing preclinical timeline by an estimated 12 months.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Research Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHenlius contracts specialized clinical research organizations (CROs) to run multi-regional trials across Asia, Europe, and North America, ensuring data meets NMPA, EMA, and FDA standards and supporting 40+ ongoing global studies as of end-2025.\u003c\/p\u003e\n\u003cp\u003eThe outsourcing model cuts fixed costs, letting Henlius advance a 30-drug pipeline while keeping R\u0026amp;D headcount lean and trimming per-trial overheads by an estimated 20–30% versus fully in-house conduct.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e40+ global studies (end-2025)\u003c\/li\u003e\n\u003cli\u003e30-drug development pipeline\u003c\/li\u003e\n\u003cli\u003e20–30% lower per-trial overhead\u003c\/li\u003e\n\u003cli\u003eRegulatory alignment: NMPA, EMA, FDA\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply Chain and Raw Material Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHenlius maintains long-term contracts with global life-science vendors for bioreactors, culture media, and consumables to secure uninterrupted COGS-sensitive production; in 2024 procurement spend on these suppliers exceeded RMB 420 million (about USD 60m), covering 95% of critical SKUs.\u003c\/p\u003e\n\u003cp\u003eThese partnerships cut supply-chain risk—supplier redundancy and JIT buffers reduced production downtime to under 1.5% in 2024, keeping batch-release quality metrics within regulatory specs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRMB 420m procurement (2024)\u003c\/li\u003e\n\u003cli\u003e95% critical SKU coverage\u003c\/li\u003e\n\u003cli\u003eDowntime \u0026lt;1.5% (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHenlius scales global biosimilars: $120M sales, 40+ trials, 30‑drug pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHenlius leverages Fosun Pharma backing (RMB 76.6bn revenue; RMB 4.8bn R\u0026amp;D, 2024) and global partners (Organon, Sandoz) to drive ~US$120m international biosimilar sales (2024), 40+ global trials (end‑2025) and a 30‑drug pipeline while cutting per‑trial overheads 20–30% and keeping production downtime \u0026lt;1.5% (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFosun Pharma revenue (2024)\u003c\/td\u003e\n\u003ctd\u003eRMB 76.6bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFosun R\u0026amp;D (2024)\u003c\/td\u003e\n\u003ctd\u003eRMB 4.8bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHenlius intl. sales (2024)\u003c\/td\u003e\n\u003ctd\u003eUS$120m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal trials (end‑2025)\u003c\/td\u003e\n\u003ctd\u003e40+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePipeline\u003c\/td\u003e\n\u003ctd\u003e30 drugs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePer‑trial overhead cut\u003c\/td\u003e\n\u003ctd\u003e20–30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduction downtime (2024)\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;1.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, investor-ready Business Model Canvas for Shanghai Henlius Biotech outlining customer segments, channels, value propositions, revenue streams, key resources, activities, partners, cost structure and governance, with integrated SWOT and competitive advantage analysis reflecting real-world R\u0026amp;D, manufacturing, and commercial strategies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eConcise one-page Business Model Canvas for Shanghai Henlius Biotech that condenses their R\u0026amp;D-driven oncology and biosimilar strategies into an editable snapshot—ideal for quick reviews, boardrooms, or team collaboration to save time and facilitate comparison.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Biopharmaceutical Research and Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHenlius focuses on advancing a pipeline of biosimilars and novel monoclonal antibodies, investing R\u0026amp;D spend of RMB 1.2 billion in 2024 to support molecular engineering and preclinical studies that target efficacy and safety benchmarks.\u003c\/p\u003e\n\u003cp\u003eThe company prioritizes unmet needs in oncology, autoimmune and ophthalmic diseases, with 14 candidates in clinical\/preclinical stages as of Dec 31, 2024, and aims to accelerate approvals to capture growing market demand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLarge Scale Biomanufacturing Operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHenlius runs GMP-certified manufacturing sites in Xuhui and Songjiang producing commercial biologics and clinical supplies; together they supported 2024 commercial output worth ~RMB 1.2 billion and supplied 18 ongoing trials. Continuous process optimization cut batch cycle time by 12% and lowered COGS per gram by ~9% in 2023–24, while meeting international release specs and FDA\/EMA-equivalent quality standards.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Clinical Trial Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAround 40–50% of Henlius’ R\u0026amp;D headcount and about CNY 1.2–1.5 billion (2024 run-rate) focus on designing and running multi‑phase, multi‑country trials, covering patient recruitment, site management, and centralized data monitoring; compliance teams manage EMA, FDA, NMPA requirements across ~20 jurisdictions. Successful pivotal results remain mandatory to secure marketing authorizations and drive peak-year sales, often in the \u0026gt;CNY 1–3 billion range per approved biologic.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercialization and Market Access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHenlius runs targeted marketing and sales to place its monoclonal antibodies and biosimilars into hospital formularies and oncology\/dermatology clinics, while negotiating with Chinese government payers for NRDL (National Reimbursement Drug List) entries—NRDL wins boosted 2024 China revenue by ~28% year-over-year.\u003c\/p\u003e\n\u003cp\u003eThey train physicians on clinical benefits and safety, and invest in brand-building to grow exports; international sales rose ~35% in 2024 as EU\/ASEAN approvals expanded market access.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNRDL inclusion drove +28% China revenue in 2024\u003c\/li\u003e\n\u003cli\u003eInternational sales +35% in 2024 after EU\/ASEAN approvals\u003c\/li\u003e\n\u003cli\u003eFocus: hospital formularies, payer negotiations, HCP education\u003c\/li\u003e\n\u003cli\u003eBrand-building fuels domestic and export growth\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Affairs and Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eNavigating NMPA, EMA, and FDA pathways is a continuous priority for Shanghai Henlius Biotech; in 2024 Henlius reported regulatory spend ~RMB 220M (≈USD 31M) and maintained 12 active MAAs\/BLAs across China, EU, and US to protect market access.\u003c\/p\u003e\n\u003cp\u003eHenlius enforces GMP-level production records and ICH-compliant safety dossiers to retain licenses and push 6 pipeline candidates through phase II\/III, targeting 2 new approvals by 2026.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRegulatory spend ~RMB 220M (2024)\u003c\/li\u003e\n\u003cli\u003e12 active MAAs\/BLAs (China\/EU\/US)\u003c\/li\u003e\n\u003cli\u003e6 pipeline candidates in phase II\/III\u003c\/li\u003e\n\u003cli\u003eTarget: 2 approvals by 2026\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHenlius: RMB1.2B R\u0026amp;D, 14 biologics, GMP cuts COGS −9%, 2 approvals targeted by 2026\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHenlius advances 14 biologic candidates (6 in Phase II\/III) with RMB 1.2B R\u0026amp;D in 2024, runs GMP sites reducing COGS −9% and supporting RMB 1.2B commercial output, and spent ~RMB 220M on regulatory work across 12 active MAAs\/BLAs; targets 2 approvals by 2026.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003eRMB 1.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePipeline\u003c\/td\u003e\n\u003ctd\u003e14 candidates\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase II\/III\u003c\/td\u003e\n\u003ctd\u003e6\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing output\u003c\/td\u003e\n\u003ctd\u003eRMB 1.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory spend\u003c\/td\u003e\n\u003ctd\u003eRMB 220M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eActive MAAs\/BLAs\u003c\/td\u003e\n\u003ctd\u003e12\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTarget approvals\u003c\/td\u003e\n\u003ctd\u003e2 by 2026\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Document Unlocks After Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document previewed here is the actual Shanghai Henlius Biotech Business Model Canvas—not a mockup—and it matches the final file you’ll receive after purchase.\u003c\/p\u003e\n\u003cp\u003eOnce you complete your order, you’ll instantly get this exact, fully editable document in the delivered formats, with all sections and content included as shown.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749067010425,"sku":"henlius-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/henlius-business-model-canvas.png?v=1772212800","url":"https:\/\/matrixbcg.com\/products\/henlius-business-model-canvas","provider":"MatrixBCG","version":"1.0","type":"link"}